NBIA Syndromes: A Step Forward from the Previous Knowledge

Area of Science:

• Neurogenetics
• Neurobiology
• Medical Imaging

Background:

• Neurodegeneration with brain iron accumulation (NBIA) encompasses rare, inherited neurological disorders characterized by abnormal iron metabolism in the brain.
• Mutations in genes regulating iron homeostasis lead to iron accumulation, often detectable via T2-weighted MRI, and are implicated in NBIA pathogenesis.
• Recent genetic findings reveal NBIA is not a single entity, with 15 distinct forms identified, primarily inherited in an autosomal recessive manner.

Purpose of the Study:

• To review the expanding clinical spectrum of NBIA syndromes.
• To discuss the genetic underpinnings and neuroimaging features of various NBIA types.
• To explore potential therapeutic targets and strategies for managing these rare neurological disorders.

Main Methods:

• Literature review of genetic discoveries and clinical case studies in NBIA.
• Analysis of neuroimaging findings, particularly MRI characteristics associated with iron accumulation.
• Synthesis of current understanding of protein dysfunction in iron homeostasis.

Main Results:

• NBIA is genetically heterogeneous, with 15 identified subtypes, most commonly pantothenate kinase-associated neurodegeneration (PKAN), phospholipase 2-associated neurodegeneration (PLAN), and mitochondrial membrane protein-associated neurodegeneration (MPAN).
• Clinical presentations are diverse, ranging from early-onset degeneration and premature death to adult-onset parkinsonism and dystonia, often accompanied by seizures, visual, and cognitive impairments.
• While often refractory to treatment, some interventions offer symptomatic relief, highlighting the need for targeted therapies.

Conclusions:

• NBIA represents a complex group of rare inherited disorders with significant clinical and genetic variability.
• Understanding the specific genetic defects and their impact on iron metabolism is crucial for diagnosis and management.
• Further research into therapeutic targets is essential to improve outcomes for patients with NBIA.